CareDx (NASDAQ:CDNA)‘s stock had its “hold” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday. They presently have a $15.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 22.55% from the company’s current price.
CDNA has been the topic of a number of other research reports. BidaskClub raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 4th. TheStreet raised shares of CareDx from a “d-” rating to a “c-” rating in a research report on Tuesday, April 10th. ValuEngine raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $17.00 target price on shares of CareDx in a research report on Wednesday, June 6th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $11.25.
NASDAQ CDNA opened at $12.24 on Thursday. The company has a current ratio of 2.43, a quick ratio of 2.06 and a debt-to-equity ratio of 0.29. The stock has a market cap of $445.27 million, a price-to-earnings ratio of -15.90 and a beta of 0.46. CareDx has a one year low of $1.05 and a one year high of $16.00.
CareDx (NASDAQ:CDNA) last posted its earnings results on Thursday, May 10th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $14.05 million for the quarter, compared to analysts’ expectations of $13.91 million. CareDx had a negative net margin of 115.91% and a negative return on equity of 158.93%. equities research analysts expect that CareDx will post -0.49 EPS for the current year.
In other news, major shareholder Neil Gagnon acquired 10,136 shares of the business’s stock in a transaction dated Thursday, April 26th. The shares were purchased at an average price of $9.42 per share, with a total value of $95,481.12. Following the transaction, the insider now directly owns 928,768 shares in the company, valued at $8,748,994.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.40% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of CDNA. Wells Fargo & Company MN grew its position in shares of CareDx by 1,360.6% in the 4th quarter. Wells Fargo & Company MN now owns 16,636 shares of the company’s stock worth $122,000 after buying an additional 15,497 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of CareDx in the 4th quarter worth approximately $534,000. BlackRock Inc. grew its position in shares of CareDx by 386.0% in the 4th quarter. BlackRock Inc. now owns 34,480 shares of the company’s stock worth $253,000 after buying an additional 27,385 shares during the last quarter. Spark Investment Management LLC grew its position in shares of CareDx by 50.0% in the 4th quarter. Spark Investment Management LLC now owns 134,408 shares of the company’s stock worth $986,000 after buying an additional 44,808 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of CareDx by 201.4% in the 4th quarter. Geode Capital Management LLC now owns 130,026 shares of the company’s stock worth $954,000 after buying an additional 86,887 shares during the last quarter. 52.55% of the stock is currently owned by hedge funds and other institutional investors.
CareDx Company Profile
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.